Skip to main content
. Author manuscript; available in PMC: 2021 Nov 23.
Published in final edited form as: Sci Transl Med. 2021 Mar 3;13(583):eabc8980. doi: 10.1126/scitranslmed.abc8980

Figure 1. Teplizumab Treatment is Associated with a Sustained Effect on Type 1 Diabetes Progression Over 923 Days of Follow-up.

Figure 1.

Updated Kaplan-Meier Curve based on 923 days of follow up (range 74-3,119 days). Hazard ratio for development of type 1 diabetes in teplizumab-treated participants vs. placebo was 0.457; p=0.01. The median time to diabetes was 27.1 and 59.6 months in the placebo and teplizumab treatment groups respectively. At the conclusion of this period, 7 (22%) and 22 (50%) respectively were not diagnosed with T1D.